Personal wellness company WeightWatchers (NASDAQ: WW) reported Q2 CY2026 results exceeding the market’s revenue expectations, but sales fell by 14.2% year on year to $162.3 million. On the other hand, the company’s full-year revenue guidance of $627.5 million at the midpoint came in 0.7% below analysts’ estimates. Its GAAP profit of $1.41 per share was significantly above analysts’ consensus estimates.

Is now the time to buy WW? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

WeightWatchers’ second quarter drew a positive market response, with management citing a deliberate shift toward higher-value membership tiers and clinical offerings as key drivers of performance. The company highlighted growth in its Core+ and Med+ subscriber bases, which offset declines in its traditional core behavioral segment. Interim Chief Operations Officer Jonathan Volkmann emphasized, “Our approach combines access to effective FDA-approved GLP-1 medications with expert guidance, setting us apart in an evolving industry landscape.”

Looking forward, WeightWatchers’ guidance is anchored on expanding its clinical segment and maintaining strong engagement in higher-value tiers while navigating a more disciplined marketing spend. Chief Financial Officer Felicia DellaFortuna stated, “We expect clinical subscription revenue to represent up to 30% of total revenue, even as subscriber growth moderates.” Management is also prioritizing operational efficiency and continued investment in technology, aiming to sustain positive operating cash flow and further reduce debt as part of its multiyear transformation plan.

Key Insights from Management’s Remarks

Management pointed to several strategic and operational factors shaping the quarter’s results and the forward outlook, particularly around mix shift and product evolution.

• Clinical business momentum: Growth in Med+ (clinical) subscriptions, supported by GLP-1 medication access and partnerships with programs like Medicare’s GLP-1 bridge, is helping WeightWatchers diversify from traditional behavioral offerings. Management noted Med+ members saw greater average weight loss compared to competitors, which is helping retention and brand differentiation.
• Behavioral tier stabilization: While legacy core subscriptions declined, the Core+ tier saw its third straight quarter of sequential subscriber growth, suggesting success in transitioning members to higher-value, more personalized services. This mix shift also drove a 10.2% increase in average revenue per user (ARPU).
• Marketing spend recalibration: The company deliberately reduced and reallocated marketing investments after a heavy Q1 focus on clinical offerings. This allowed for more balanced growth across segments and helped align spending with seasonal demand patterns.
• Operational efficiency initiatives: Structural changes, including workflow automation and a focused technology roadmap, enabled WeightWatchers to maintain gross margins near historical highs despite higher staffing costs in clinical services. DellaFortuna highlighted the ability to hold adjusted gross margins steady as a key operational achievement.
• Debt reduction and cash flow: WeightWatchers reduced its term loan principal by over $41 million in the quarter, generating savings on interest and strengthening liquidity. Management underscored ongoing discipline in capital allocation and a commitment to positive operating cash flow, supporting future investments.

Drivers of Future Performance

WeightWatchers’ outlook is shaped by continued clinical expansion, a higher-value subscriber mix, and disciplined cost management amid a shifting competitive landscape.

• Clinical revenue growth focus: Management anticipates clinical subscriptions will comprise up to 30% of annual revenue, reflecting ongoing integration of GLP-1 medication support and new partnerships like Sam’s Club. However, moderation in clinical subscriber growth is expected due to lower planned marketing spend and lapping of last year’s long-term commitment offers.
• Behavioral segment evolution: The company expects continued growth in Core+ subscribers alongside a slower rate of decline in traditional behavioral memberships. This supports ARPU growth and a more resilient revenue base, even as the overall behavioral segment contracts.
• Margin management and investment priorities: WeightWatchers projects slight gross margin compression as a result of the higher clinical mix, but intends to keep adjusted gross margins above 72%. Operating expenses, particularly marketing, will be managed carefully, with second-half spend expected to be lower than the first half. Technology and product development remain prioritized for sustaining competitive differentiation.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will focus on (1) further progress in shifting subscribers toward higher-value Core+ and clinical tiers, (2) the sustainability of gross margins amid evolving business mix and cost structure, and (3) the effectiveness of partnerships like the Medicare GLP-1 bridge and Sam’s Club in attracting and retaining members. Execution in technology upgrades and continued debt reduction will also be closely monitored.

WeightWatchers currently trades at $16.01, up from $15.32 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.